Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 22;53(8):gkaf346.
doi: 10.1093/nar/gkaf346.

The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing

Jillian Belgrad  1   2 , Erin McConnell  2   3 , Stef Leonard  2 , Nicole Nolen  2 , Marlen C Lauffer  2   4 , Jonathan K Watts  1   2 , Timothy Yu  2   5   6 , Winston X Yan  2 , Annemieke Aartsma-Rus  2   4
Affiliations
Review

The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing

Jillian Belgrad et al. Nucleic Acids Res. .

Erratum in

Abstract

Developing customized gene-targeting therapies for the millions of individuals affected by ultra-rare diseases globally requires breaking new ground in therapeutic and regulatory innovation. To address this need, the N=1 Collaborative (N1C) was established to unite academia, industry, patients, and regulators, building an open, shared ecosystem for personalized medicines. Initially focusing on antisense oligonucleotides (ASOs) for rare, fatal neurodegenerative conditions, the N1C aims to develop frameworks that can rapidly extend to other treatment modalities and conditions. Progress in the advancement of personalized therapies has also propelled advancements in the nucleic acids field, offering critical insights into dosing, safety, and efficacy. In October 2024, the N1C convened scientific, regulatory, and advocacy leaders in ASO development for an inaugural meeting. This review report examines the current state of the scientific and clinical ecosystems enabling customized genetic therapies and explores the innovation, frameworks, and systems needed to deliver additional individualized medicines safely and at scale.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Graphical Abstract
Graphical Abstract
See this image and copyright information in PMC

References

    1. Kim J, Woo S, de Gusmao CM et al. A framework for individualized splice-switching oligonucleotide therapy. Nature. 2023; 619:828–36. 10.1038/s41586-023-06277-0. - DOI - PMC - PubMed
    1. Aartsma-Rus A FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther. 2017; 27:67–9. 10.1089/nat.2017.0665. - DOI - PubMed
    1. Aartsma-Rus A, Collin RWJ, Elgersma Y et al. Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics. Ther Adv Rare Dis. 2024; 5:26330040241273465. - PMC - PubMed
    1. Crooke ST, Kim-McManus OS, Dalby K A way forward for diagnosis of patients with extremely rare genetic mutations. Nat Biotechnol. 2023; 41:1190–2. 10.1038/s41587-023-01879-5. - DOI - PubMed
    1. Aartsma-Rus A, Garanto A, van Roon-Mom W et al. Consensus guidelines for the design and in vitro preclinical efficacy testing N-of-1 exon skipping antisense oligonucleotides. Nucleic Acid Ther. 2023; 33:17–25. 10.1089/nat.2022.0060. - DOI - PMC - PubMed

MeSH terms

Substances